Abeona Therapeutics (ABEO) Gross Margin (2011 - 2026)

Abeona Therapeutics' Gross Margin history runs 9 years deep, the most recent figure standing at 69.08% for Q1 2026.

• On a quarterly basis, Gross Margin changed N/A year-over-year to 69.08% in Q1 2026; TTM through Mar 2026 was 70.23%, a N/A change from a year earlier, with the FY2025 full-year figure at 73.68%, changed N/A from the prior year.
• Gross Margin fell to 69.08% in Q1 2026 per ABEO's latest filing, from 80.74% in the prior quarter.
• Across five years, Gross Margin topped out at 80.74% in Q4 2025 and bottomed at 47.06% in Q4 2022.
• The 4-year median for Gross Margin is 67.04% (2022), against an average of 49.63%.
• Biggest YoY gain for Gross Margin was 1000 bps in 2023; the steepest drop was 1000 bps in 2023.
• Year by year, Gross Margin stood at 47.06% in 2022, then soared by 217 bps to 55.0% in 2023, then soared by 47 bps to 80.74% in 2025, then declined by 14 bps to 69.08% in 2026.
• Per Business Quant, the three latest ABEO Gross Margin figures stand at 69.08% (Q1 2026), 80.74% (Q4 2025), and 75.0% (Q2 2025).